Business Marketing




AFL & NRL Premiership winning coaches Chris Scott and Trent Robinson have joined the growing list of sporting stars throwing their names behind sports science company Levin Health, in a bid to help break the stigma around medicinal cannabis.

The coaching royalty are aiming to raise awareness of medicinal cannabis as a potential treatment option for those suffering from different health conditions.

Mr Scott, who steered the Cats to a momentous 133 to 52 AFL premiership victory against the Sydney Swans this year, said he had invested in Levin Health because he was interested in the medicinal cannabis sector and the potential benefits of medicinal cannabis for athletes.

I invested in Levin Health after becoming interested in the medicinal cannabis sector and what the findings could mean for professional athletes. Levin Health is investing in research at La Trobe University which is important,” said Mr Scott.

Lauren Jackson's circumstance has intrigued me and I’m interested to learn more about what implications her experience will have for athletes in the future.”

The growing all-star lineup of sporting and business personalities to join Levin Health ranks includes Sydney Roosters three-time NRL premiership-winning coach Trent Robinson.

The Dally M Coach of the Year recipient and Levin Health shareholder joined the Roosters as Head Coach in 2013 and is the longest-serving Head Coach in the Club’s 114-year history, having steered the team to an impressive 250 games.

According to current TGA data, chronic pain is the leading factor for medicinal cannabis prescriptions, with more than 100,000 new prescriptions in 2022 alone for the condition.*

Levin Health CEO Mark Brayshaw said a growing number of Australians were becoming aware of medicinal cannabis as an alternative treatment option for a range of health conditions, helped in part by advocacy efforts including from sporting greats like Chris Scott and Trent Robinson.

Levin Health continues to investigate the efficacy of medicinal cannabis products for the treatment of pain, mental health disorders and sport-related ailments and we are heartened by the sheer volume of support we continue to receive from well-known athletes and coaches,” said Mr Brayshaw.

The high-profile support we continue to receive will help to reduce stigma around medicinal cannabis and help our mission to improve people’s quality of life through our world-leading clinical studies involving medicinal cannabis treating conditions such as chronic pain, concussion and sports injuries,” concluded Mr Brayshaw.

The list of sporting greats to join the Levin Health ranks in support of medicinal cannabis include Adam Gilchrist, Chris Scott, Andrew Johns. Lauren Jackson, Damien Oliver, Alastair Clarkson, Damien Hardwick, James Brayshaw, John Longmire and Trent Robinson.

Disclaimer: The information contained within this article does not take the place of professional or medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition, and whether or not a particular treatment is right for you. For the latest information regarding accessing medicinal cannabis, visit the Therapeutic Goods Administration (TGA) website at


About Levin Health:
Levin Health is an Australian sports science company focused on evidence-based research, development and commercialisation of medicinal cannabis products initially for the treatment of pain, mental health disorders and sport-related ailments. Its purpose is to help people to improve their lifestyle.

The Company will complete a world-leading clinical trial investigating the efficacy of its patented medicinal cannabis formula, clinically validating its use in the treatment of pain and secondary indications, such as anxiety, stress and insomnia. Upon the anticipated competition of the Phase 2a trial in 2023, Levin Health will leverage its prominent sport and medical contacts to deliver on its commercialisation strategy of providing direct patient access in Australia and overseas.

Completion of this trial will provide a breadth of clinically-validated data currently lacking in the medicinal cannabis market which is expected to reach over US$1.5 billion in Australia alone, and US$103 billion globally by 2024. Levin Health currently has a range of prescription products available under the Levin™ brand accessible through the Special Access Scheme. All products are made in Australian GMP-certified facilities with Australian cannabis. They are committed to developing and providing the best cannabis-based medicine possible.
Instagram: @LevinHealth
Facebook: @LevinHealth
Twitter: @LevinHealth
LinkedIn: @Levin-Health
YouTube: Levin Health

Business Marketing